Literature DB >> 15217737

Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates.

Donato Cioli1, Sanaa S Botros, Katherine Wheatcroft-Francklow, Amadou Mbaye, Vaughan Southgate, Louis-Albert Tchuem Tchuenté, Livia Pica-Mattoccia, Anna Rita Troiani, Sayed H Seif El-Din, Abdel-Nasser A Sabra, Jan Albin, Dirk Engels, Michael J Doenhoff.   

Abstract

The dose of praziquantel required to kill 50% of adult worms in vivo (i.e. the ED50) was estimated for nine different isolates of Schistosoma mansoni in infected mice. Four of the isolates were selected because they had not knowingly been in contact with the drug (i.e. they were putatively praziquantel-susceptible). Five putatively praziquantel-resistant isolates were chosen because they had been selectively bred for drug-resistance in the laboratory and/or had previously been shown to be relatively resistant to praziquantel in the field. The work was performed in three laboratories in different countries using pre-agreed and comparable experimental protocols. All four praziquantel-susceptible isolates had ED50s estimated to be <100 mg/kg (mean=70+/-7 SD; median=68), while all five putatively praziquantel-resistant isolates had estimated ED50s >100 mg/kg (mean=209+/-48 SD; median=192). Thus, the five praziquantel-resistant isolates, including two that had been subjected to drug pressure during more than 20 passages in mice, had drug ED50s that were approximately three times as great as those of the praziquantel-susceptible isolates. Two of the five isolates in the putatively resistant group had previously been passaged 15 or more times in mice without administration of drug-pressure, but had ED50s consistent with the other three isolates in the group, indicating that the trait of praziquantel-resistance did not necessarily impair biological fitness during laboratory passage. The protocols used here to estimate the praziquantel ED50s of S. mansoni isolates should be useful for establishing and monitoring the drug susceptibility/resistance profiles of parasite isolates freshly obtained from endemic areas, particularly those in which increased usage of the drug is likely to occur.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217737     DOI: 10.1016/j.ijpara.2004.05.001

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  44 in total

1.  Immunohistopathological changes in murine Schistosomiasis mansoni under the influence of N-acetyl-L-cysteine.

Authors:  André de Lima Aires; Mônica Camelo Pessôa de Azevedo Albuquerque; Renata Alexandre Ramos Silva; Giuliana Viegas Schirato; Nicodemos Teles de Pontes Filho; Sidcley Bernardino de Araújo; Valdênia Maria Oliveira Souza; Vlaudia Maria Assis Costa; Elizabeth Malagueño
Journal:  Parasitol Res       Date:  2012-07-07       Impact factor: 2.289

2.  Integration of reporter transgenes into Schistosoma mansoni chromosomes mediated by pseudotyped murine leukemia virus.

Authors:  Kristine J Kines; Maria E Morales; Victoria H Mann; Geoffrey N Gobert; Paul J Brindley
Journal:  FASEB J       Date:  2008-04-10       Impact factor: 5.191

3.  Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.

Authors:  Gina S El-Feky; Wael S Mohamed; Hanaa E Nasr; Naglaa M El-Lakkany; Sayed H Seif El-Din; Sanaa S Botros
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 4.  Susceptibility Testing of Medically Important Parasites.

Authors:  Abebe Genetu Bayih; Anjan Debnath; Edward Mitre; Christopher D Huston; Benoît Laleu; Didier Leroy; Benjamin Blasco; Brice Campo; Timothy N C Wells; Paul A Willis; Peter Sjö; Wesley C Van Voorhis; Dylan R Pillai
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

5.  Ultrastructural changes of adult Schistosoma mansoni worms recovered from C57BL/6 mice passively immunized with normal and vaccinated rabbit sera in vivo.

Authors:  Sherif H Abdeen; Enayat S Reda; Eman A El-Shabasy; Allal Ouhtit
Journal:  Parasitol Res       Date:  2011-05-26       Impact factor: 2.289

6.  Effect of praziquantel on adult Echinostoma paraensei worms in experimentally infected mice.

Authors:  Juliana Ferraz; Joyce Souza; Michele Costa-Silva; Eduardo Torres; André Santana; Reinalda Lanfredi; Arnaldo Maldonado; Juberlan Garcia
Journal:  Parasitol Res       Date:  2012-01-17       Impact factor: 2.289

7.  Pharmacokinetics of the Antischistosomal Lead Ozonide OZ418 in Uninfected Mice Determined by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Anna Leonidova; Mireille Vargas; Jörg Huwyler; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Molecular and functional characterization of a putative PA28γ proteasome activator orthologue in Schistosoma mansoni.

Authors:  Cláudia Sossai Soares; Enyara Rezende Morais; Lizandra G Magalhães; Carla Botelho Machado; Érika Bueno de Carvalho Moreira; Felipe Roberti Teixeira; Vanderlei Rodrigues; Timothy P Yoshino
Journal:  Mol Biochem Parasitol       Date:  2013-04-20       Impact factor: 1.759

9.  In vitro praziquantel test capable of detecting reduced in vivo efficacy in Schistosoma mansoni human infections.

Authors:  Poppy H L Lamberton; Sarah C Hogan; Narcis B Kabatereine; Alan Fenwick; Joanne P Webster
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

10.  Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Authors:  Sandra D Melman; Michelle L Steinauer; Charles Cunningham; Laura S Kubatko; Ibrahim N Mwangi; Nirvana Barker Wynn; Martin W Mutuku; Diana M S Karanja; Daniel G Colley; Carla L Black; William Evan Secor; Gerald M Mkoji; Eric S Loker
Journal:  PLoS Negl Trop Dis       Date:  2009-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.